SAVA Stock Alert: Cassava Sciences Pops on Late-Stage Trial Update

On top of that, the company is expecting a second clinical trial to be ready in June 2025. This is split on a onefor-one-for-one basis between two doses of simufilam and a placebo. There are 1,125 patients in this trial. SAVA stock is also up 29% as of Monday afternoon. However, its shares are still down 42% since the start of the year. Read More:Penny Stocks — How to Profit Without Getting Scammed "Our board of directors is 100% committed to completing our Phase 3 program and releasing those results on a t ...